AR066212A1 - Formas cristalinas de ester 4-(nitrooxi ) butilico de atorvastatina - Google Patents

Formas cristalinas de ester 4-(nitrooxi ) butilico de atorvastatina

Info

Publication number
AR066212A1
AR066212A1 ARP080101528A ARP080101528A AR066212A1 AR 066212 A1 AR066212 A1 AR 066212A1 AR P080101528 A ARP080101528 A AR P080101528A AR P080101528 A ARP080101528 A AR P080101528A AR 066212 A1 AR066212 A1 AR 066212A1
Authority
AR
Argentina
Prior art keywords
forms
ester
nitrooxi
butilico
atorvastatina
Prior art date
Application number
ARP080101528A
Other languages
English (en)
Spanish (es)
Inventor
Fabio Nicoli
Stefano Biondi
Annalisa Bonfanti
Francesca Benedini
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of AR066212A1 publication Critical patent/AR066212A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP080101528A 2007-04-13 2008-04-11 Formas cristalinas de ester 4-(nitrooxi ) butilico de atorvastatina AR066212A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90766407P 2007-04-13 2007-04-13

Publications (1)

Publication Number Publication Date
AR066212A1 true AR066212A1 (es) 2009-08-05

Family

ID=39590250

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101528A AR066212A1 (es) 2007-04-13 2008-04-11 Formas cristalinas de ester 4-(nitrooxi ) butilico de atorvastatina

Country Status (15)

Country Link
US (1) US20100152274A1 (zh)
EP (1) EP2137146B1 (zh)
JP (1) JP2010523612A (zh)
KR (1) KR20090128423A (zh)
CN (1) CN101668740A (zh)
AR (1) AR066212A1 (zh)
AU (1) AU2008238143A1 (zh)
BR (1) BRPI0809849A2 (zh)
CA (1) CA2681596A1 (zh)
IL (1) IL200856A0 (zh)
MX (1) MX2009011009A (zh)
NZ (1) NZ579736A (zh)
RU (1) RU2009139179A (zh)
WO (1) WO2008125412A1 (zh)
ZA (1) ZA200906468B (zh)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040101229A (ko) * 2002-02-14 2004-12-02 랜박시 래보러터리스 리미티드 알칼리 금속 첨가에 의해 안정화된 아토르바스타틴 배합물
US7166638B2 (en) * 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
CA2539158A1 (en) * 2003-09-17 2005-03-24 Warner-Lambert Company Llc Crystalline forms of ['r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
ES2262459T1 (es) * 2004-07-22 2006-12-01 Teva Pharmaceutical Industries Ltd Nuevas formas cristalinas de atorvastatina semicalcica y procedimientos para su preparacion.
EP1928823B1 (en) * 2005-08-15 2014-10-08 Arrow International Limited Process for preparing crystalline sodium salt of ATORVASTATIN
US8084488B2 (en) * 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
KR20080097989A (ko) * 2006-02-03 2008-11-06 니콕스 에스. 에이. 근위축증 치료를 위한 의약의 니트록시 유도체의 용도

Also Published As

Publication number Publication date
BRPI0809849A2 (pt) 2014-09-23
ZA200906468B (en) 2010-05-26
MX2009011009A (es) 2009-10-30
IL200856A0 (en) 2010-05-17
US20100152274A1 (en) 2010-06-17
JP2010523612A (ja) 2010-07-15
EP2137146B1 (en) 2012-05-30
RU2009139179A (ru) 2011-05-20
AU2008238143A1 (en) 2008-10-23
NZ579736A (en) 2012-02-24
KR20090128423A (ko) 2009-12-15
EP2137146A1 (en) 2009-12-30
CN101668740A (zh) 2010-03-10
CA2681596A1 (en) 2008-10-23
WO2008125412A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
EA201070158A1 (ru) Сульфонамиды в качестве trpm8 модуляторов
WO2010109334A3 (en) Thienopyrimidinedione derivatives as trpa1 modulators
UY30320A1 (es) Formas polimorficas de 1-((4-metil-quinazolin-2-il)metil)--3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)-xantina, preparaciones, composiciones de preparacion y aplicaciones de las mismas.
BR0210666A (pt) Formas cristalinas do sal de cálcio do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
CR20110314A (es) Compuestos orgánicos
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
EA200702586A1 (ru) Кристаллические модификации пираклостробина
BRPI0514731A (pt) derivados de pirimidina
WO2007022225A3 (en) Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2005016876A3 (en) Cyclic amine bace-1 inhibitors having a benzamide substituent
BRPI0616111B8 (pt) derivados de carboxamida, composição farmacêutica, uso dos mesmos e combinação
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
AR074694A1 (es) Sal de hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico, y otras formas cristalinas de la misma.
UY31419A1 (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen
TW200716568A (en) 1H-quinazoline-2,4-diones
BR112012033291A2 (pt) derivados de 3-amino-5,6-di-hidro-1h-piranzin-2-ona úteis para o tratamento de doença de alzheimer e outras formas de demência
ECSP056193A (es) Derivados sustituidos del pirrol
WO2007070562A3 (en) Non-hygroscopic compositions of enterostatin
EA201491102A1 (ru) Производные 5-(3-аминофенил)-5-алкил-5,6-дигидро-2h-[1,4]оксазин-3-амина
WO2019224790A3 (en) Prodrugs of fulvestrant
WO2008100618A3 (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
WO2007079119A3 (en) Process for manufacturing picolinate borinic esters
WO2009147009A3 (en) Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
ATE496025T1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern

Legal Events

Date Code Title Description
FA Abandonment or withdrawal